TitovVN, MalyshevPP, AmelyushkinaVA, AripovskyAV, SmirnovGP, PolevayaTY, et al.: The effect of statins: activation of lipolysis and absorption by insulin-dependent cells. Klin Lab Diagn, 2015; 60:4–12 [Article in Russian].
2.
SchmidtSL, BessesenDH, StotzS, PeelorFF3rd, MillerBF, HortonTJ: Adrenergic control of lipolysis in women compared with men. J Appl Physiol (1985), 2014; 117:1008–1019.
3.
HahnKA, OgilvieG, RuskT, DevauchelleP, LeblancA, LegendreA, et al.: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med, 2008; 22:1301–1309.
4.
HumbertM, de BlayF, GarciaG, Prud'hommeA, LeroyerC, MagnanA, et al.: Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy, 2009; 64:1194–1201.
5.
PaulC, SansB, SuarezF, CasassusP, BareteS, LanternierF, et al.: Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol, 2010; 85:921–925.
6.
MouraDS, SultanS, Georgin-LavialleS, PilletN, MontestrucF, GinesteP, et al.: Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One, 2011; 6:e26375.
7.
LortholaryO, ChandesrisMO, Bulai LivideanuC, PaulC, GuilletG, JassemE, et al.: Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet, 2017; 389:612–620.
8.
MeltzerHY: New trends in the treatment of schizophrenia. CNS Neurol Disord Drug Targets, 2017. DOI: 10.2174/1871527316666170728165355 [PMID: 28758583].
9.
ZhangG, StackmanRWJr: The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol, 2015; 6:225.
10.
KrishnanN, BenczeG, CohenP, TonksNK: The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases. FEBS J, 2013; 280:2830–2841.
11.
MilenkovićM, Arsenović-RaninN, VucićevićD, BufanB, JancićI, Stojić-VukanićZ: Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis. Arch Med Res, 2008; 39:639–646.
12.
GhashghaeiniaM, GiustariniD, KoralkovaP, KöberleM, AlzoubiK, BissingerR, et al.: Pharmacological targeting of glucose-6-phosphate dehydrogenase in human erythrocytes by Bay 11-7082, parthenolide and dimethyl fumarate. Sci Rep, 2016; 6:28754.
13.
LinG, BornfeldtKE: Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux. Biochem Biophys Res Commun, 2002; 290:663–669.
14.
Türker-KayaS, Komsuoğlu Celikyurtİ, CelikyurtU, KınaA: Inhibition of PDE4 by low doses of rolipram induces changes in lipid and protein components of mice heart. Gen Physiol Biophys, 2017. DOI: 10.4149/gpb_2017009. [Epub ahead of print] [PMID: 28836502].
15.
HonoratJA, KinoshitaM, OkunoT, TakataK, KodaT, TadaS, et al.: Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. PLoS One, 2013; 8:e71329.
16.
NakatsuY, SenoY, KushiyamaA, SakodaH, FujishiroM, KatasakoA, et al.: The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol, 2015; 309:G42–G51.
17.
NovackGD, LewisRA, VogelR, ShethN, SwearingenD, RasmussenS: Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther, 2013; 29:674–680.
18.
Dal MonteM, FilippiL, BagnoliP: Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn Schmiedebergs Arch Pharmacol, 2013; 386:269–278.
19.
OikawaF, NakaharaT, AkanumaK, UedaK, MoriA, SakamotoK, et al.: Protective effects of the β3-adrenoceptor agonist CL316243 against N-methyl-D-aspartate-induced retinal neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol, 2012; 385:1077–1081.
20.
JinY, SilvermanAJ, VannucciSJ: Mast cell stabilization limits hypoxic-ischemic brain damage in the immature rat. Dev Neurosci, 2007; 29:373–384.
21.
StrbianD, KovanenPT, Karjalainen-LindsbergML, TatlisumakT, LindsbergPJ: An emerging role of mast cells in cerebral ischemia and hemorrhage. Ann Med, 2009; 41:438–450.
22.
LindsbergPJ, StrbianD, Karjalainen-LindsbergML: Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab, 2010; 30:689–702.
23.
McKittrickCM, LawrenceCE, CarswellHV: Mast cells promote blood brain barrier breakdown and neutrophil infiltration in a mouse model of focal cerebral ischemia. J Cereb Blood Flow Metab, 2015; 35:638–647.
24.
HoriY, TakedaS, ChoH, WegmannS, ShoupTM, TakahashiK, et al.: A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid β in the brain in a transgenic model of Alzheimer disease. J Biol Chem, 2015; 290:1966–1978.
25.
AliMK, KimRY, KarimR, MayallJR, MartinKL, ShahandehA, et al.: Role of iron in the pathogenesis of respiratory disease. Int J Biochem Cell Biol, 2017; 88:181–195.
26.
GhioAJ, HilbornED: Indices of iron homeostasis correlate with airway obstruction in an NHANES III cohort. Int J Chron Obstruct Pulmon Dis, 2017; 12:2075–2084.
27.
GozzelinoR, ArosioP: Iron homeostasis in health and disease. Int J Mol Sci, 2016; 17. pii: E130.
28.
KhiroyaH, TurnerAM: The role of iron in pulmonary pathology. Multidiscip Respir Med, 2015; 10:34.
29.
CloonanSM, GlassK, Laucho-ContrerasME, BhashyamAR, CervoM, PabónMA, et al.: Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med, 2016; 22:163–174.
30.
SuterMR, KirschmannG, LaedermannCJ, AbrielH, DecosterdI: Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology, 2013; 118:160–172.
31.
NovakKR, NormanJ, MitchellJR, PinterMJ, RichMM: Sodium channel slow inactivation as a therapeutic target for myotonia congenita. Ann Neurol, 2015; 77:320–332.
32.
SkovM, de PaoliFV, NielsenOB, PedersenTH: The anti-convulsants lacosamide, lamotrigine, and rufinamide reduce myotonia in isolated human and rat skeletal muscle. Muscle Nerve, 2017; 56:136–142.
33.
ReillySM, ChiangSH, DeckerSJ, ChangL, UhmM, LarsenMJ, et al.: An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nat Med, 2013; 19:313–321.
34.
ChangKC, ShiehB, PetrashJM: Influence of aldose reductase on epithelial-to-mesenchymal transition signaling in lens epithelial cells. Chem Biol Interact, 2017; 276:149–154.
35.
ChaBK, KimYS, HwangKE, ChoKH, OhSH, KimBR, et al.: Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget, 2016; 7:57213–57227.
36.
OhlmannA, ScholzM, KochM, TammER: Epithelial-mesenchymal transition of the retinal pigment epithelium causes choriocapillaris atrophy. Histochem Cell Biol, 2016; 146:769–780.
37.
Domek-ŁopacińskaKU, StrosznajderJB: Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol Neurobiol, 2010; 41:129–137.
38.
Komsuoglu-CelikyurtI, GocmezSS, MutluO, GacarN, AriciogluF, UtkanT: Evidence for the involvement of neuronal nitric oxide synthase and soluble guanylate cyclase on cognitive functions in rats. Life Sci, 2011; 89:905–910.
